Preliminary Price-Adjustment Factors (Based on Forecast Inflation Rates)
Table 1 reproduces preliminary price-adjustment factors for 2013 published in the April 2012 NEWSletter. These factors were based on forecasted annual CPI-inflation rates of 2.1% and 2.0% for 2012 and 2013, respectively.
Forecast 2013 Price-Adjustment Factors for Patented Drug Products
Benchmark Year |
(1) 2010 |
(2) 2011 |
(3) 2012 |
Price-Adjustment Factor |
1.072 |
1.041 |
1.020 |
These figures imply (1) a maximum allowable cumulative price increase between 2010 and 2013 of 7.2% for patented drug products with Canadian sales in 2010 (that is, products whose “benchmark year” is 2010); (2) a maximum allowable cumulative price increase between 2011 and 2013 of 4.1% for products whose first Canadian sales occurred in 2011; and (3) a maximum allowable cumulative price increase between 2012 and 2013 of 2.0% for products whose first Canadian sales occurred in 2012.
In addition, the forecast inflation rate of 2.0% for 2013 implies a year-over-year price increase cap (applicable to all drug products, regardless of benchmark year) of 3.0% (= 1.5 x 2.0%) for 2013.
Final Price-Adjustment Factors (Based on Actual Inflation Rates)
The actual rate of CPI inflation for 2012 of 1.5% was published in the January 2013 NEWSletter. The actual rate of CPI inflation for 2013 is now available and was 0.9%. These rates (along with the actual 2011 CPI-inflation rate of 2.9%) yield the following final price-adjustment factors.
Final 2013 Price-Adjustment Factors for Patented Drug Products
(Based on Actual CPI-Inflation Rates for 2012 and 2013)
Benchmark Year |
(1) 2010 |
(2) 2011 |
(3) 2012 |
Price-Adjustment Factor |
1.055 |
1.025 |
1.009 |
The final year-over-year price increase cap for 2013 is 1.4% (= 1.5 x 0.9%).